Aerosol characterization of nebulized intranasal glucocorticoid formulations.
Inhaled glucocorticoids (GCs) are the mainstay of long-term therapy for asthma. The lack of suitable preparations in the United States has induced clinicians to use intranasal (IN) GC formulations as "nebulizer suspensions" for off-label therapy. However, no data are available regarding aerosol production and characteristics. The aim of this study was to characterize drug outputs and aerodynamic profiles of four nebulized IN GC formulations with further analysis of flunisolide (Flu), and to test the influence of different delivery system/formulation combinations. The aerodynamic profiles and drug outputs were determined by impaction and chemical analysis. The solution output was determined by the gravimetric technique. Triamcinole acetonide (TAA), fluticasone propionate (Flut), beclomethasone dipropionate (Bec), and Flu (550, 500, 840, and 250 microg, respectively) diluted to 4 mL with saline solution were tested with the Sidestream (SID) and Aero-Tech II (AT2) nebulizers. Subsequently, Flu was tested with four additional nebulizers (Pari LC + [PARI] Acorn II, Hudson T Up-draft II, and Raindrop). All the aerosols were heterodisperse and had a particle size range optimal for peripheral airway deposition (1.85 to 3.67 microm). Flu had the highest drug output in the respirable range (22.8 and 20.3 microg/min with the AT and SID, respectively). Flu was 5-11 times more efficiently nebulized than the other formulations tested. No differences were detected in the solution outputs (0.25 to 0.3 mL/min). In subsequent testing of Flu, the PARI, AT, and SID showed the best performances. The LC+ achieved the highest drug and solution output (27.4 microg/min and 0.89 mL/min, respectively). In conclusion, Flu showed the best aerosol performance characteristics. These data do not endorse the off-label utilization of nebulized IN GC, but underscores the importance of in vitro testing before selecting any formulation/nebulizer combinations for clinical use.
Berlinski
A
A
Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA.
Waldrep
J C
JC
D000280:Administration, Inhalation; D000281:Administration, Intranasal; D000336:Aerosols; D000704:Analysis of Variance; D000730:Androstadienes / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D001507:Beclomethasone / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D002626:Chemistry, Pharmaceutical; D004353:Drug Evaluation, Preclinical; D016903:Drug Monitoring; D000068298:Fluticasone; D006801:Humans; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D014018:Tissue Distribution; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*
D000336:Aerosols; D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone; D014222:Triamcinolone Acetonide; D001507:Beclomethasone